FDA Re-arms DSaRM: Recruits Eight Veterans from Safety/Surveillance World
This article was originally published in RPM Report
The new group of Drug Safety & Risk Management Advisory Committee members comprises a lot of familiar faces. FDA has made use of its extensive outside academic connections, research grants and post-graduate training programs to bring in eight members for the Classes of 2013 and 2014. Most of them have been getting extensive on-the-job training with the advisory committee already.
You may also be interested in...
FDA faces a tough decision on Avandia. Should it stay or should it go? There is bigger underlying issue: should the standard be different for pulling a drug than it is for approving the drug in the first place? It may be counterintuitive, but a different standard makes sense.
Bruce Psaty, longtime advocate of increased post-market safety controls for drugs, sees big challenges looming for FDA as it tries to adapt to the new authorities granted by the 2007 Food & Drug Administration Amendments Act. Psaty views the establishment of a large 100-million-life post-market surveillance system as a particularly daunting challenge.
The decision by FDA to add another "black box" warning to GalxoSmithKline's diabetes drug shows where the drug safety group stands on the agency's totem pole.